Results 121 to 130 of about 5,919,627 (334)

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

Molecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne   +61 more
wiley   +1 more source

Adjuvant chemotherapy for rectal cancer with complete pathological response (pCR) may not be necessary: a pooled analysis of 5491 patients

Cancer Cell International, 2019
Background It is recommended postoperative adjuvant chemotherapy for all rectal cancers undergoing neo-chemoradiotherapy regardless of the final yield pathology.
Xiang Hu, Ya-Qi Li, Xiao-ji Ma, Long Zhang, San-Jun Cai, Jun-Jie Peng   +5 more
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative surgery for colon cancer [PDF]

, 2009
<b>Aim</b>: To comprehensively compare the prognostic value of tumour and patient-related factors in patients undergoing curative surgery for colon cancer.
Benson, Brown, Compton, Cooper, Crozier, Dukes, Forrest, Gabay, Gasser, Halazun, Hauser, Ishizuka, Kacevska, Kandemir, Kim, Kobayashi, Lee, Leitch, Lindmark, Maltoni, McMillan, McMillan, Mehrkhani, Michael, Moertel, Monreal, Morris, Petrelli, Ramsey, Roxburgh, Sasaki, Sharma, Smith, Taylor, Thynne, Vakkila, Vibert, Viganó, Walsh, Wanebo, Wang, Wolpin   +41 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study

ImmunoTargets and Therapy
Zhi-Gang Hong,1,2,&ast; Binyi Xiao,1,2,&ast; Muxu Zheng,1,2,&ast; Wanjun Yang,1,2,&ast; Liangjun Zhu,3 Guodong Liang,4 Yuhao Luo,5 Jinghua Tang,1,2 Weijian Mei,1,2 Jie-Hai Yu,1,2 Zhenlin Hou,1,2 Xiaojun Wu,1,2 Peirong Ding,1,2 Wu Jiang1,2
Hong ZG, Xiao B, Zheng M, Yang W, Zhu L, Liang G, Luo Y, Tang J, Mei W, Yu JH, Hou Z, Wu X, Ding P, Jiang W   +13 more
doaj  

Resection of the urinary bladder for locally advanced colorectal cancer: a retrospective comparison of partial versus total cystectomy

BMC Surgery, 2019
Background The postoperative and survival outcomes of patients with primary advanced colorectal cancer who undergo partial versus total cystectomy have not been adequately compared, as studies of this topic are rare and comprise relatively small cohorts.
Akihiro Kondo, Takeshi Sasaki, Daichi Kitaguchi, Yuichiro Tsukada, Yuji Nishizawa, Masaaki Ito   +5 more
doaj   +1 more source

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources